Dupilumab in patients with cold urticaria: Results from a phase 3 trial

20260 citationsJournal Articlegold Open Access

Authors

Martin Metz · Humboldt-Universität zu Berlin

Sarbjit S. Saini · Johns Hopkins University

Akiko YAGAMI · Fujita Health University

Rémi Gagnon

Ana M. Giménez-Arnau · Universitat Pompeu Fabra

Xiaodong Luo · Morristown Medical Center

Lacey B. Robinson · Sanofi (France)

Abstract

Dupilumab treatment did not lead to statistically significant improvements in signs and symptoms of ColdU as compared with placebo over the 24-week treatment period.

Topics & Keywords

Urticaria and Related Conditions Drug-Induced Adverse Reactions Dermatology and Skin Diseases

UN Sustainable Development Goals

Zero hunger

Publication Details

Published in: Journal of Allergy and Clinical Immunology Global

Volume 5, Issue 3, pp. 100673-100673

DOI: 10.1016/j.jacig.2026.100673

Field-Weighted Citation Impact: 0.00